← Leaderboards
Scott James Weir
University Of Kansas Medical Center
$2,961,565
Attributed
$5,420,153
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $976.4K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,420,153 · 6
By mechanism
R01$2,558,460 · 1
R44$1,912,633 · 1
P30$545,999 · 2
UL1$334,563 · 1
U13$68,498 · 1
Top collaborators
- Shrikant Anant5 shared
- William Mc Culloch2 shared
- Richard J. Barohn1 shared
- Andrew K Godwin1 shared
Most similar at University Of Kansas Medical Center
Same institution · by research overlap
- Jill Reeves Hamilton-Reeves$4,131,817
- Gregory Allen Reed$1,847,421
- Paul Toren$553,203
- Amanda Elizabeth Brinker$504,563
- Michael Jay Baltezor$302,257
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroIn VivoClinical TrialsPharmaceutical PreparationsPre-ClinicalLeadKansasNotch ProteinUniversitiesBiological MarkersMalignant NeoplasmsDrug TargetingDrug DiscoveryCancer CenterDesignAreaProgramsPreclinical StudyProteinsDrug DevelopmentNovel Therapeutic InterventionCancer TherapyClinical ResearchDrug Kinetics
Grant awards (16)
Lead Development & Optimization Shared Resource$123,337
P30 · FY2025 · CA · contact PI
Lead Development & Optimization Shared Resource$121,746
P30 · FY2024 · CA · contact PI
Lead Development & Optimization Shared Resource$120,192
P30 · FY2023 · CA · contact PI
Development of Ciclopirox Prodrug as a Novel Systemic Treatment for High-Risk Non-Muscle Invasive Bladder Cancer$976,393
R44 · FY2021 · CA
Development of Ciclopirox Prodrug as a Novel Systemic Treatment for High-Risk Non-Muscle Invasive Bladder Cancer$936,240
R44 · FY2020 · CA
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy$661,842
R01 · FY2018 · CA
Drug Discovery, Delivery, & Experimental Therapeutics Research Program$73,510
P30 · FY2018 · CA · contact PI
Drug Discovery, Delivery, & Experimental Therapeutics Research Program$16,666
P30 · FY2018 · CA · contact PI
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy$688,666
R01 · FY2017 · CA
Drug Discovery, Delivery, & Experimental Therapeutics Research Program$83,018
P30 · FY2017 · CA · contact PI
Drug Discovery, Delivery, & Experimental Therapeutics Research Program$7,530
P30 · FY2017 · CA · contact PI
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy$628,483
R01 · FY2016 · CA
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy$67,777
R01 · FY2015 · CA
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy$511,692
R01 · FY2014 · CA
Drug Repurposing and Rediscovery for Gastrointestinal Stromal Tumors$334,563
UL1 · FY2012 · TR
Annual Conference on Development of Robust Experimental Assay Methods (DREAM)$68,498
U13 · FY2011 · MH · contact PI